Concepedia

Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy

Ranjit Nair, Gaëlle Drillet, Faustine Lhomme, Anthony Le Bras, Laure Michel, John M. Rossi, Marika Sherman, Allen Xue, A. Kerber, Nutchawan Jittapiromsak,

Haematologica · 2020 · 32 citations · 8 references

DOIFull text

Open access

Concepts

Abstract

Chimeric antigen receptor (CAR) T-cell therapy maybe associated with neurologic toxicity, also referred to as immune effector cell-associated neurotoxicity syndrome (ICANS), 1,2 that typically manifests as encephalopathy.

References

8

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text

, , +16

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson et al. · The Lancet · 2014 · 2.9K citations

, , +17

Current concepts in the diagnosis and management of cytokine release syndrome

Daniel W. Lee, Rebecca Gardner, David Porter et al. · Blood · 2014 · 2.8K citations

, , +14

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations

, , +12

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

Margherita Norelli, Barbara Camisa, Giulia Barbiera et al. · Nature Medicine · 2018 · 1.4K citations

, , +16